Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.

Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.

Abstract: Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Fuel protection apparatus and related systems for use with vehicles are disclosed. A disclosed vehicle includes a fuel component in an engine compartment of the vehicle. The vehicle also includes a spacer coupled to a cam carrier and positioned proximate to the fuel component. The vehicle also includes a protector coupled to a cylinder head and spaced from the spacer and the cam carrier. The protector is configured to receive a load from a cowl brace or firewall of the vehicle during a vehicle impact event in which an engine assembly of the vehicle moves relative to the cowl brace or firewall. The protector is configured to transfer the load to the cylinder head, the cam carrier, and the spacer to protect the fuel component.

Abstract: Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.

Abstract: Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, N—Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Fuel protection apparatus and related systems for use with vehicles are disclosed. A disclosed vehicle includes a fuel component in an engine compartment of the vehicle. The vehicle also includes a spacer coupled to a cam carrier and positioned proximate to the fuel component. The vehicle also includes a protector coupled to a cylinder head and spaced from the spacer and the cam carrier. The protector is configured to receive a load from a cowl brace or firewall of the vehicle during a vehicle impact event in which an engine assembly of the vehicle moves relative to the cowl brace or firewall. The protector is configured to transfer the load to the cylinder head, the cam carrier, and the spacer to protect the fuel component.

Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.

Abstract: Arrangements described herein can control audio within a vehicle by stopping sound from two or more audio sources based on one quiet-all input. Systems can output sound via one or more speakers in response to audio signals from two or more audio sources. A quiet-all input can be received via a user interface, where the quiet-all input is a single input to stop sound from the two or more audio sources. Responsive to receiving the quiet-all input, all sound output through the one or more speakers from the two or more audio sources can be stopped or reduced to a predetermined volume.

Abstract: The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.

Abstract: Arrangements described herein can control audio within a vehicle by stopping sound from two or more audio sources based on one quiet-all input. Systems can output sound via one or more speakers in response to audio signals from two or more audio sources. A quiet-all input can be received via a user interface, where the quiet-all input is a single input to stop sound from the two or more audio sources. Responsive to receiving the quiet-all input, all sound output through the one or more speakers from the two or more audio sources can be stopped or reduced to a predetermined volume.

Abstract: The present invention relates to the use of mutants of parathyroid hormone-related protein, to treat disorders associated with smooth muscle cells, and to inhibit the cellular activation and proliferation thereof. The method can be employed in diverse tissues to effect therapeutic and prophylactic relief for disorders and diseases manifested by activation of smooth muscle that can lead to excessive smooth muscle proliferation. For example, where employed in the vasculature, the inventive method can be used to treat restenosis following angioplasty.

Abstract: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

Abstract: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

Abstract: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

Abstract: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

Abstract: There is disclosed the nucleic acid and amino acid sequences for the human PTH-Like Peptide and derivatives. PTH-Like Peptide is the humoral mediator of humoral hypercalcemia of malignany or HHM which is common in patients with squamous carcinomas or renal, bladder or ovarian carcinomas with little or no evidence of skeletal disease.